Published in Stroke on March 01, 2002
Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol (2010) 4.37
Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol (2007) 3.33
Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience (2008) 2.55
Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke (2008) 2.10
Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury. J Clin Invest (2007) 1.84
Brain angiogenesis in developmental and pathological processes: neurovascular injury and angiogenic recovery after stroke. FEBS J (2009) 1.82
Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci (2006) 1.69
The neurovascular unit and combination treatment strategies for stroke. Trends Pharmacol Sci (2012) 1.66
Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke (2009) 1.56
Normobaric hyperoxia attenuates early blood-brain barrier disruption by inhibiting MMP-9-mediated occludin degradation in focal cerebral ischemia. J Neurochem (2009) 1.53
Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential. Stroke (2009) 1.30
Invited article: searching for oracles? Blood biomarkers in acute stroke. Neurology (2009) 1.24
Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front Neurol (2013) 1.23
Mmp-9 inhibition: a therapeutic strategy in ischemic stroke. Mol Neurobiol (2013) 1.22
Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage. J Cereb Blood Flow Metab (2010) 1.19
An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke (2012) 1.18
Experimental models, neurovascular mechanisms and translational issues in stroke research. Br J Pharmacol (2007) 1.14
Progesterone and allopregnanolone attenuate blood-brain barrier dysfunction following permanent focal ischemia by regulating the expression of matrix metalloproteinases. Exp Neurol (2010) 1.13
Neuroprotective effects of overexpressing tissue inhibitor of metalloproteinase TIMP-1. J Neurotrauma (2009) 1.12
Effect of neutrophil depletion on gelatinase expression, edema formation and hemorrhagic transformation after focal ischemic stroke. BMC Neurosci (2005) 1.11
Neutrophils contribute to intracerebral haemorrhages after treatment with recombinant tissue plasminogen activator following cerebral ischaemia. Br J Pharmacol (2009) 1.10
Inhibition of VEGF signaling pathway attenuates hemorrhage after tPA treatment. J Cereb Blood Flow Metab (2011) 1.07
The growth factor progranulin attenuates neuronal injury induced by cerebral ischemia-reperfusion through the suppression of neutrophil recruitment. J Neuroinflammation (2013) 1.07
Feasibility of minocycline and doxycycline use as potential vasculostatic therapy for brain vascular malformations: pilot study of adverse events and tolerance. Cerebrovasc Dis (2008) 1.07
Hydrogen gas reduced acute hyperglycemia-enhanced hemorrhagic transformation in a focal ischemia rat model. Neuroscience (2010) 1.04
Neuroprotection for stroke: current status and future perspectives. Int J Mol Sci (2012) 1.04
Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke. Stroke (2010) 1.03
Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns. J Neurosci (2009) 1.02
Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke. J Pharmacol Exp Ther (2009) 1.02
Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats. Exp Neurol (2008) 1.00
Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS One (2010) 1.00
Lycium barbarum extracts protect the brain from blood-brain barrier disruption and cerebral edema in experimental stroke. PLoS One (2012) 0.99
The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity. J Cereb Blood Flow Metab (2010) 0.99
Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Vasc Health Risk Manag (2009) 0.98
Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats. J Cereb Blood Flow Metab (2009) 0.98
Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis? J Cereb Blood Flow Metab (2014) 0.97
Neurovascular matrix metalloproteinases and the blood-brain barrier. Curr Pharm Des (2012) 0.96
Does inhibiting Sur1 complement rt-PA in cerebral ischemia? Ann N Y Acad Sci (2012) 0.96
Matrix metalloproteinase-2 or -9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusion. Neuroscience (2012) 0.96
Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin Ther Targets (2008) 0.95
Adult neural stem cells: response to stroke injury and potential for therapeutic applications. Curr Stem Cell Res Ther (2011) 0.95
Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence. J Neuroinflammation (2011) 0.95
Inflammation in adult and neonatal stroke. Clin Neurosci Res (2006) 0.94
Hypothermia after acute ischemic stroke. J Neurotrauma (2009) 0.91
RNA in blood is altered prior to hemorrhagic transformation in ischemic stroke. Ann Neurol (2013) 0.91
Putative role of prostaglandin receptor in intracerebral hemorrhage. Front Neurol (2012) 0.90
Brain arteriovenous malformation modeling, pathogenesis, and novel therapeutic targets. Transl Stroke Res (2014) 0.90
Molecular pathophysiology of cerebral edema. J Cereb Blood Flow Metab (2015) 0.89
Angiogenesis-regulating microRNAs and Ischemic Stroke. Curr Vasc Pharmacol (2015) 0.89
Window of opportunity: estrogen as a treatment for ischemic stroke. Brain Res (2013) 0.88
Increased plasma and tissue MMP levels are associated with BCSFB and BBB disruption evident on post-contrast FLAIR after experimental stroke. J Cereb Blood Flow Metab (2010) 0.88
Critical role of matrix metalloprotease-9 in chronic high fat diet-induced cerebral vascular remodelling and increase of ischaemic brain injury in mice†. Cardiovasc Res (2014) 0.87
Matrix metalloproteinase 2 (MMP-2) degrades soluble vasculotropic amyloid-beta E22Q and L34V mutants, delaying their toxicity for human brain microvascular endothelial cells. J Biol Chem (2010) 0.87
Infrared optical imaging of matrix metalloproteinases (MMPs) up regulation following ischemia reperfusion is ameliorated by hypothermia. BMC Neurosci (2012) 0.87
Quantitative MRI reveals the elderly ischemic brain is susceptible to increased early blood-brain barrier permeability following tissue plasminogen activator related to claudin 5 and occludin disassembly. J Cereb Blood Flow Metab (2011) 0.86
Multimodal neuroprotective therapy with induced hypothermia after ischemic stroke. Stroke (2008) 0.85
Normobaric hyperoxia-based neuroprotective therapies in ischemic stroke. Med Gas Res (2013) 0.85
Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke: a proof-of-concept study. J Neurol (2009) 0.85
One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke. Curr Neuropharmacol (2017) 0.84
Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocycline. Pharmacotherapy (2010) 0.84
Matrix metalloproteinases: drug targets for myocardial infarction. Curr Drug Targets (2013) 0.84
Vascular protection to increase the safety of tissue plasminogen activator for stroke. Curr Pharm Des (2012) 0.83
Effect of glibenclamide on the prevention of secondary brain injury following ischemic stroke in humans. Neurosurg Focus (2014) 0.83
Physiological and pathological roles of tissue plasminogen activator and its inhibitor neuroserpin in the nervous system. Front Cell Neurosci (2015) 0.83
Systems pharmacology dissection of multi-scale mechanisms of action for herbal medicines in stroke treatment and prevention. PLoS One (2014) 0.82
17β-estradiol attenuates breakdown of blood-brain barrier and hemorrhagic transformation induced by tissue plasminogen activator in cerebral ischemia. Neurobiol Dis (2011) 0.81
Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke. Front Cell Neurosci (2016) 0.81
A new embolus injection method to evaluate intracerebral hemorrhage in New Zealand white rabbits. Brain Res (2010) 0.79
Excess salt increases infarct size produced by photothrombotic distal middle cerebral artery occlusion in spontaneously hypertensive rats. PLoS One (2014) 0.79
Hemostasis and alterations of the central nervous system. Semin Thromb Hemost (2013) 0.79
Hemorrhagic Transformation after Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke: Mechanisms, Models, and Biomarkers. Mol Neurobiol (2014) 0.79
A radical scavenger edaravone inhibits matrix metalloproteinase-9 upregulation and blood-brain barrier breakdown in a mouse model of prolonged cerebral hypoperfusion. Neurosci Lett (2014) 0.78
Biomarkers in neurocritical care. Neurotherapeutics (2012) 0.78
Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia. Stroke (2015) 0.78
Role of matrix metalloproteinase activity in the neurovascular protective effects of Angiotensin antagonism. Stroke Res Treat (2014) 0.78
Coadministration of FTY720 and rt-PA in an experimental model of large hemispheric stroke-no influence on functional outcome and blood-brain barrier disruption. Exp Transl Stroke Med (2013) 0.78
A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury. Br J Pharmacol (2015) 0.77
Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers. J Cereb Blood Flow Metab (2016) 0.77
Critical role of sphingosine-1-phosphate receptor-2 in the disruption of cerebrovascular integrity in experimental stroke. Nat Commun (2015) 0.76
THE AUTODIGESTION HYPOTHESIS AND RECEPTOR CLEAVAGE IN DIABETES AND HYPERTENSION. Drug Discov Today Dis Models (2011) 0.76
Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocycline. Rev Neurol Dis (2010) 0.75
Adverse outcome of early recurrent ischemic stroke secondary to atrial fibrillation after repeated systemic thrombolysis. Case Rep Vasc Med (2013) 0.75
Gelatinase activity imaged by activatable cell-penetrating peptides in cell-based and in vivo models of stroke. J Cereb Blood Flow Metab (2015) 0.75
Comment on roles of tissue plasminogen activator and its inhibitor in proliferative diabetic retinopathy. Int J Ophthalmol (2016) 0.75
Trans-sodium crocetinate provides neuroprotection against cerebral ischemia and reperfusion in obese mice. J Neurosci Res (2014) 0.75
Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection. Cerebrovasc Dis Extra (2016) 0.75
Matrix metalloproteinases in cerebral ischemia. J Clin Neurol (2006) 0.75
Pivotal neuroinflammatory and therapeutic role of high mobility group box 1 in ischemic stroke. Biosci Rep (2017) 0.75
Low Serum Albumin level as a Predictor of Hemorrhage Transformation after Intravenous Thrombolysis in Ischemic Stroke Patients. Sci Rep (2017) 0.75
Critical role of matrix metallopeptidase 9 in postoperative cognitive dysfunction and age-dependent cognitive decline. Oncotarget (2017) 0.75
Upregulation of Matrix Metalloproteinase-9 in Primary Cultured Rat Astrocytes Induced by 2-Chloroethanol Via MAPK Signal Pathways. Front Cell Neurosci (2017) 0.75
Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke (2009) 6.79
The science of stroke: mechanisms in search of treatments. Neuron (2010) 6.14
Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med (2006) 5.10
Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med (2008) 3.83
Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med (2003) 3.10
A pilot study of normobaric oxygen therapy in acute ischemic stroke. Stroke (2005) 2.58
Two-photon high-resolution measurement of partial pressure of oxygen in cerebral vasculature and tissue. Nat Methods (2010) 2.37
Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke (2006) 2.27
Effects of neuroglobin overexpression on acute brain injury and long-term outcomes after focal cerebral ischemia. Stroke (2008) 2.25
Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis. Neurology (2012) 2.19
Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke (2004) 2.13
Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke (2008) 2.10
Neuroprotection via matrix-trophic coupling between cerebral endothelial cells and neurons. Proc Natl Acad Sci U S A (2008) 2.06
Correlation between brain reorganization, ischemic damage, and neurologic status after transient focal cerebral ischemia in rats: a functional magnetic resonance imaging study. J Neurosci (2003) 2.05
Cortical spreading depression activates and upregulates MMP-9. J Clin Invest (2004) 1.93
Normobaric hyperoxia improves cerebral blood flow and oxygenation, and inhibits peri-infarct depolarizations in experimental focal ischaemia. Brain (2007) 1.92
Cell-cell signaling in the neurovascular unit. Neurochem Res (2007) 1.92
Stimulus-induced changes in blood flow and 2-deoxyglucose uptake dissociate in ipsilateral somatosensory cortex. J Neurosci (2008) 1.89
Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J Neurosci (2006) 1.85
Brain angiogenesis in developmental and pathological processes: neurovascular injury and angiogenic recovery after stroke. FEBS J (2009) 1.82
The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab (2004) 1.80
Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol (2008) 1.79
Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke (2005) 1.77
Normobaric hyperoxia reduces MRI diffusion abnormalities and infarct size in experimental stroke. Neurology (2002) 1.67
Developmentally regulated role for Ras-GRFs in coupling NMDA glutamate receptors to Ras, Erk and CREB. EMBO J (2004) 1.65
An oligovascular niche: cerebral endothelial cells promote the survival and proliferation of oligodendrocyte precursor cells. J Neurosci (2009) 1.62
Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol (2010) 1.62
Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol Sci (2008) 1.62
Green tea polyphenol (-)-epigallocatechin gallate reduces neuronal cell damage and up-regulation of MMP-9 activity in hippocampal CA1 and CA2 areas following transient global cerebral ischemia. J Neurosci Res (2009) 1.60
Effects of normobaric hyperoxia in a rat model of focal cerebral ischemia-reperfusion. J Cereb Blood Flow Metab (2002) 1.59
OCT methods for capillary velocimetry. Biomed Opt Express (2012) 1.57
Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J Neurosci (2004) 1.56
Astrocytic induction of matrix metalloproteinase-9 and edema in brain hemorrhage. J Cereb Blood Flow Metab (2006) 1.56
Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog Neurobiol (2002) 1.55
Baicalein and 12/15-lipoxygenase in the ischemic brain. Stroke (2006) 1.50
Experimental model of warfarin-associated intracerebral hemorrhage. Stroke (2008) 1.48
Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia. Brain Res (2005) 1.47
Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke (2007) 1.47
Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke. J Cereb Blood Flow Metab (2010) 1.44
Hemoglobin-induced cytotoxicity in rat cerebral cortical neurons: caspase activation and oxidative stress. Stroke (2002) 1.43
Normobaric hyperoxia extends the reperfusion window in focal cerebral ischemia. Ann Neurol (2005) 1.42
Triggers and mediators of hemorrhagic transformation in cerebral ischemia. Mol Neurobiol (2003) 1.40
Biphasic actions of HMGB1 signaling in inflammation and recovery after stroke. Ann N Y Acad Sci (2010) 1.39
Relaxation-compensated fast multislice amide proton transfer (APT) imaging of acute ischemic stroke. Magn Reson Med (2008) 1.39
Association between pH-weighted endogenous amide proton chemical exchange saturation transfer MRI and tissue lactic acidosis during acute ischemic stroke. J Cereb Blood Flow Metab (2011) 1.36
Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke (2007) 1.35
Novel lipoxygenase inhibitors as neuroprotective reagents. J Neurosci Res (2008) 1.34
Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes. Glia (2003) 1.32
High-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia. Stroke (2010) 1.30
Dysfunctional cell-cell signaling in the neurovascular unit as a paradigm for central nervous system disease. Stroke (2008) 1.29
Inhibition of reactive astrocytes with fluorocitrate retards neurovascular remodeling and recovery after focal cerebral ischemia in mice. J Cereb Blood Flow Metab (2009) 1.27
Acute plasmalemma permeability and protracted clearance of injured cells after controlled cortical impact in mice. J Cereb Blood Flow Metab (2007) 1.27
Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Stroke (2009) 1.26
Effects of neuroglobin overexpression on mitochondrial function and oxidative stress following hypoxia/reoxygenation in cultured neurons. J Neurosci Res (2009) 1.25
Protecting against cerebrovascular injury: contributions of 12/15-lipoxygenase to edema formation after transient focal ischemia. Stroke (2008) 1.25
Astrocytic high-mobility group box 1 promotes endothelial progenitor cell-mediated neurovascular remodeling during stroke recovery. Proc Natl Acad Sci U S A (2012) 1.24
TNF alpha and Fas mediate tissue damage and functional outcome after traumatic brain injury in mice. J Cereb Blood Flow Metab (2007) 1.23
Induction of caspase-mediated cell death by matrix metalloproteinases in cerebral endothelial cells after hypoxia-reoxygenation. J Cereb Blood Flow Metab (2004) 1.21
Infarct prediction and treatment assessment with MRI-based algorithms in experimental stroke models. J Cereb Blood Flow Metab (2006) 1.20
Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab (2005) 1.18
Mechanisms and targets for angiogenic therapy after stroke. Cell Adh Migr (2009) 1.17
Mitogen-activated protein kinase inhibition in traumatic brain injury: in vitro and in vivo effects. J Cereb Blood Flow Metab (2002) 1.15
12/15-Lipoxygenase targets neuronal mitochondria under oxidative stress. J Neurochem (2009) 1.13
Neuroprotective effects of overexpressing tissue inhibitor of metalloproteinase TIMP-1. J Neurotrauma (2009) 1.12
A rat model of studying tissue-type plasminogen activator thrombolysis in ischemic stroke with diabetes. Stroke (2011) 1.12
Secretion of matrix metalloproteinase-2 and -9 after mechanical trauma injury in rat cortical cultures and involvement of MAP kinase. J Neurotrauma (2002) 1.11
Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation (2011) 1.10
Characterization of cerebrovascular responses to hyperoxia and hypercapnia using MRI in rat. Neuroimage (2008) 1.10
Role of ERK map kinase and CRM1 in IL-1beta-stimulated release of HMGB1 from cortical astrocytes. Glia (2010) 1.09
CD47 gene knockout protects against transient focal cerebral ischemia in mice. Exp Neurol (2009) 1.09
Astrocytes protect oligodendrocyte precursor cells via MEK/ERK and PI3K/Akt signaling. J Neurosci Res (2010) 1.08
Vascular endothelial growth factor regulates the migration of oligodendrocyte precursor cells. J Neurosci (2011) 1.08
The brain's heart - therapeutic opportunities for patent foramen ovale (PFO) and neurovascular disease. Pharmacol Ther (2013) 1.07
Crosstalk between oligodendrocytes and cerebral endothelium contributes to vascular remodeling after white matter injury. Glia (2012) 1.07
Oxidative stress interferes with white matter renewal after prolonged cerebral hypoperfusion in mice. Stroke (2013) 1.07
Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab (2011) 1.06
Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro. Brain Res (2009) 1.06
Oligovascular signaling in white matter stroke. Biol Pharm Bull (2009) 1.06
Plasma-type gelsolin is decreased in human blood and cerebrospinal fluid after subarachnoid hemorrhage. Stroke (2011) 1.06
Plasmalemma permeability and necrotic cell death phenotypes after intracerebral hemorrhage in mice. Stroke (2011) 1.06
Inhibition of 12/15-lipoxygenase as therapeutic strategy to treat stroke. Ann Neurol (2012) 1.05
Cellular mechanisms of neurovascular damage and repair after stroke. J Child Neurol (2011) 1.05
Stroke: working toward a prioritized world agenda. Stroke (2010) 1.05
Proteasome inhibition protects HT22 neuronal cells from oxidative glutamate toxicity. J Neurochem (2005) 1.05
Pathophysiologic cascades in ischemic stroke. Int J Stroke (2012) 1.03
Intracranial hemorrhage: mechanisms of secondary brain injury. Acta Neurochir Suppl (2011) 1.03
Genetic analysis of the role of tumor necrosis factor receptors in functional outcome after traumatic brain injury in mice. J Neurotrauma (2010) 1.03
Oligodendrocyte precursors induce early blood-brain barrier opening after white matter injury. J Clin Invest (2013) 1.02
Optical coherence tractography using intrinsic contrast. Opt Lett (2012) 1.02
Interleukin-1beta augments angiogenic responses of murine endothelial progenitor cells in vitro. J Cereb Blood Flow Metab (2009) 1.02
Increased nuclear apoptosis-inducing factor after transient focal ischemia: a 12/15-lipoxygenase-dependent organelle damage pathway. J Cereb Blood Flow Metab (2010) 1.02
Multiparametric, longitudinal optical coherence tomography imaging reveals acute injury and chronic recovery in experimental ischemic stroke. PLoS One (2013) 1.02
Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury. J Neurotrauma (2002) 1.01
Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats. Stroke (2013) 1.01
Stroke: working toward a prioritized world agenda. Cerebrovasc Dis (2010) 1.01
Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators. Neurosci Lett (2007) 1.01